Chembio Diagnostics Inc 's ROA from the fourth quarter of 2022 to the fourth quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Chembio Diagnostics Inc 's ROA in the fourth quarter of 2022?
Chembio Diagnostics Inc recorded a cumulative net loss of $-23 million during 12 months ending in the fourth quarter of 2022, resulting in a negative return on assets (ROA) of -38.22%.

However, within the Healthcare sector 664 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2022 from 4964 to 5192.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter
Y / Y Total Assets Change	-14.53 %	-26.01 %	13.07 %	9.54 %	12.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-23	-36	-36	-38	-34
Return On Assets (TTM)	-38.22 %	-57.25 %	-52.24 %	-56.63 %	-51.31 %
CEMI's Total Ranking	# 5192	# 4964	# 5043	# 5047	# 5329
Total Assets (TTM) in million	63	62	56	63	73
Seq. Total Assets Change	0.69 %	10.93 %	-10.87 %	-14.15 %	-12.84 %
Seq. Net Income Change	-	-	-	-	-

CEMI's 5 Years Annual ROA >> Back to CEMI Management Effectiveness >> Compare CEMI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 272
Sector	# 665
Overall	# 5034

Return On Assets Statistics
High	Average	Low
6.21 %	-27.43 %	-76.31 %
(Sep 30 2013)		(Mar 31 2017)

Financial Statements
Chembio Diagnostics Inc 's Assets	$ 63 million	CEMI's Balance sheet
Chembio Diagnostics Inc 's Income	$ -1 million	Quarterly CEMI's Income Statement
CEMI's Income by Division		See CEMI's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018
Y / Y Total Assets Change	-14.53 %	12.88 %	16.44 %	36.22 %	146.21 %
Total Assets in million	63	73	65	56	41
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-23	-34	-26	-14	-8
Annual Return On Assets	-37.2 %	-46.28 %	-39.33 %	-24.54 %	-19.23 %

CEMI's 5 Years Annual ROA >> Back to CEMI Management Effectiveness >> Compare CEMI ROA to its Competitors

More Return On Assets Ratios
CEMI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CEMI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CEMI's Competitors
Subscribers only: Roa for Chembio Diagnostics Inc 's Suppliers
Subscribers only: Return On Assets for CEMI's Customers

You may also want to know
CEMI's Roi	CEMI's Inventory Turnover Ratio	CEMI's Growth Rates	CEMI's Dividend Comparisons
	CEMI's Profitability Ratios	CEMI's Asset Turnover Ratio	CEMI's Dividend Growth
CEMI's Roe	CEMI's Valuation Ratios	CEMI's Financial Strength Ratios	CEMI's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2022, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:10:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.